DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对患者肺
功能的影响
孙江涛;乔艳萍
【期刊名称】《中国实用医刊》 【年(卷),期】2018(045)018
【摘要】目的 探讨DC-CIK联合化疗在晚期非小细胞肺癌患者中的临床疗效及对患者肺功能的影响.方法 选择2016年2月至2018年1月入院治疗的晚期非小细胞肺癌患者100例作为对象,根据治疗方案分为对照组和观察组,每组50例.对照组采用常规化疗治疗,观察组在对照组基础上联合DC-CIK治疗,两组均连续治疗3个月,治疗完毕后对患者效果进行评估.采用platinumEliteDL型肺功能测定仪测定两组治疗前、治疗后3个月第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及二者比值(FEV1/FVC)水平;采用酶联免疫吸附试验测定两组治疗前、治疗后3个月白细胞介素-2(IL-2)、IL-6、IL-10及肿瘤坏死因子-α(TNF-α)水平;记录并统计两组治疗后3个月骨髓抑制、恶心呕吐、白细胞减少及血小板减少毒副反应发生率.结果 观察组与对照组治疗后3个月FEV1/FVC水平比较差异未见统计学意义(P>0.05);观察组与对照组治疗后3个月FEV1、FVC水平,均高于治疗前(P<0.05);观察组治疗后3个月FEV1、FVC水平均高于对照组(P<0.05);观察组治疗后3个月IL-2、TNF-α水平均高于对照组(P<0.05);观察组治疗后3个月IL-6、IL-10水平低于对照组(P<0.05);观察组治疗后3个月骨髓抑制、恶心呕吐、白细胞减少及血小板减少毒副反应发生率与对照组比较差异未见统计学意义(P>0.05).结论 将DC-CIK联合化疗用于晚期非小细胞肺癌患者中有助于改善患者肺功能,降低炎症因子水平,且并未增加毒副反应发生率,值
得推广应用.%Objective To investigate the clinical efficacy of DC-CIK combined with chemotherapy on patients with advanced non-small cell lung cancer and its influence on lung function .Methods A total of 100 patients with advanced non-small cell lung cancer who were admitted to hospital from February 2016 to January 2018 were selected as the subjects .According to the treatment plan , they were divided into control group and observation group , with 50 cases in each group .The control group was treated with conventional chemotherapy , and the observation group was treated with DC-CIK on the basis of the control group.Both groups were continuously treated for 3 months.After the treatment was completed , the effects were evaluated .Platinum Elite D-type pulmonary function tester was used to measure the forced expiratory volume (FEV1), forced vital capacity (FVC), and the ratio of the two (FEV1/FVC) at 1 second before treatment and 3 months after treatment;and by enzyme-linked immunosorbent assay ( ELISA) .The levels of interleukin-2(IL-2), interleukin-6, interleukin-10, and tumor necrosis factor-a (TNF-a) levels were measured before and after treatment in both groups; the two groups were recorded and counted after treatment . The incidences of bone marrow suppression , nausea and vomiting , leukopenia , and thrombocytopenia toxicity reactions at 3 months were compared . Results There was no significant difference in FEV1/FVC levels between the observation group and the control group
at 3 months after treatment ( P>0.05 ) .The FEV1 and FVC levels in the observation group and the control group at 3 months after treatment were higher than those before treatment ( P<0.05 );the FEV1 and FVC levels in the observation group were higher than those in the control group at 3 months after treatment (P<0.05). The IL-2 and TNF-αlevels were higher in the observation group at 3 months after treatment than those in the control group (P<0.05).The levels of IL-6 and IL-10 were lower in the observation group at 3 months after treatment than those in the control group ( P<0.05 ) .At 3 months after treatment , there was no significant difference in the incidences of bone marrow suppression , nausea and vomiting , leukopenia or thrombocytopenia toxicity side effects between the two groups (P>0.05).Conclusions The application of DC-CIK combined with chemotherapy in patients with advanced non -small cell lung cancer can improve the lung function of patients , reduce the level of inflammatory factors , and does not increase the incidence of adverse reactions .It is worthy of popularization and application . 【总页数】4页(24-27)
【关键词】DC-CIK;化疗;晚期非小细胞肺癌;临床疗效;肺功能;炎症因子;毒副反应
【作者】孙江涛;乔艳萍
【作者单位】264400 山东省威海市中心医院肿瘤科;264400 山东省威海市中心医院肿瘤科
DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对患者肺功能的影响
